China Resources Double-Crane Pharmaceutical Co 600062.SS · CNY
Health Care · Shanghai · 🇨🇳 China
15.84
-1.43%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About China Resources Double-Crane Pharmaceutical Co
Its shares trade on Shanghai under the ticker 600062.SS. It has been listed since 22 May 1997. In the fiscal year to 31 December 2025, it reported revenue of CN¥11.00bn and net income of CN¥1.65bn. At that date it held total assets of CN¥17.01bn and shareholders' equity of CN¥11.63bn.
China Resources Double-Crane Pharmaceutical Co., Ltd. engages in the processing, manufacture, and sale of pharmaceutical, chemical, and biomedical raw materials. The company is headquartered in Beijing, Beijing. is a China-based company principally engaged in the development, manufacture and distribution of pharmaceuticals. The firm's main businesses are classified into three segments: Chronic Disease segment, Specialist segment and Infusion segment. Chronic Disease segment mainly provides products for lowering blood pressure, blood fat and blood glucose. Specialist segment mainly involves in the research, development and distribution of pharmaceuticals targeting six areas, including cardiovascular and cerebrovascular, pediatrics, kidney disease, mental/nerve, anesthesia and analgesia and respiratory areas. Infusion segment various types of infusion products, such as basic infusion, therapeutic infusion and nutritional. The firm distributes its products mainly in domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 22 May 1997
- Employees
- 11,821
- Website
- dcpc.com ↗
Leadership
Pay as last reported
- Mr. Wenchao LuChairman of the Board, since 2017CN¥2.3m
- Mr. Qian ZhaoPresident, Director, since 2024
- Mr. Wenhao HuangChief Financial Officer, Finance Director
- Mr. Ju LiuVice President, Secretary of the Board
- Ms. Ziqin LiuVice PresidentCN¥1.6m
- Mr. Chao ManVice PresidentCN¥1.8m
- Mr. Hekai TanVice PresidentCN¥1.1m
- Ms. Donghan YaoVice PresidentCN¥923,000
- Mr. Xiaosong BaiDirector
- Mr. Xiangming LiDirector
- Mr. Guolong LinDirector
- Mr. Hui XuDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 84
- Environment
- 99
- Social
- 87
- Governance
- 66
- Direct emissions (scope 1)
- 58,154.59 t
- Energy emissions (scope 2)
- 239,685.11 t
- Value chain emissions (scope 3)
- 0 t
- Women in the workforce
- 49.00104%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Chronic Disease segment offers blood pressure, blood fat, and blood glucose products.
- Specialist segment covers cardiovascular, pediatrics, and kidney disease pharmaceuticals.
- Infusion segment provides basic, therapeutic, and nutritional infusion products.
Weaknesses
- Chronic Disease segment focuses on domestic market distribution only.
- Specialist segment targets six specific medical areas without global expansion.
- Infusion segment lacks international market presence beyond China.
Opportunities
- Chronic Disease segment can expand into global markets for blood pressure products.
- Specialist segment may grow in cardiovascular and respiratory areas internationally.
- Infusion segment could enter international markets with nutritional infusion products.
Threats
- Chronic Disease segment faces domestic market saturation for blood glucose products.
- Specialist segment encounters competition in cardiovascular and pediatrics areas.
- Infusion segment risks market saturation in basic infusion product segment.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.